HYDERABAD, Feb 8 (Reuters) - Indian biopharmaceutical
company Biocon Ltd BION.NS swung to a third-quarter profit on
Thursday, boosted by its biosimilars business and the sale of
some of its non-core units, and said Chief Financial Officer
Indranil Sen had resigned.
Sen, who has been with the company for nearly a decade,
resigned from the role to pursue career opportunities outside of
Biocon, it said. He will be with the company until March 15.
For the latest quarter, the Bengaluru-based company reported
a consolidated net profit of 6.6 billion rupees ($79.6 million),
compared with a loss of 418 million rupees a year earlier.
"Steady market shares for key biosimilars in the U.S. and EU
were complemented by the Emerging Markets performance which saw
a number of new product launches and tender wins," Biocon
Executive Chairperson Kiran Mazumdar Shaw said.
Revenue from operations surged 34% to 39.54 billion rupees,
with its largest segment, biosimilars, reporting a 64.8%
increase in revenue to 24.83 billion rupees.
Biosimilars are copies of costlier biological drugs made
from living cells, primarily used in treating major ailments
such as cancer and rheumatoid arthritis. The acquisition of
U.S.-based Viatris also helped drive growth at the main
business.
The generics segment reported a 7.5% fall in revenue.
The company also recorded gains of 3.5 billion rupees
from the sale of its dermatology and nephrology branded
formulation businesses to Eris Lifesciences ERIS.NS during the
quarter and 4.56 billion rupees from stake dilution in its
subsidiary, Bicara Therapeutics.
Shares of Biocon closed 1.9% lower on Thursday.
($1 = 82.9680 Indian rupees)
(Reporting by Rishika Sadam; Editing by Dhanya Ann Thoppil and
Anil D'Silva)
((Rishika.S@thomsonreuters.com;))